- Home
- IRON
IRON
Disc Medicine Inc.
as 03-25-2025 11:35am EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.9B | IPO Year: | N/A |
| Target Price: | $83.80 | AVG Volume (30 days): | 347.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.60 - $68.73 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | IRON | Director | Mar 19 '25 | Sell | $54.01 | 52,429 | $2,831,986.74 | 488,617 | |
| Ashiya Mona | IRON | Director | Mar 19 '25 | Sell | $54.01 | 52,429 | $2,831,986.74 | 484,264 | |
| ORBIMED ADVISORS LLC | IRON | Director | Mar 10 '25 | Sell | $54.56 | 312,384 | $16,965,596.07 | 488,617 | |
| Ashiya Mona | IRON | Director | Mar 10 '25 | Sell | $54.56 | 312,384 | $16,965,596.07 | 484,264 | |
| Quisel John D | IRON | Chief Executive Officer | Feb 18 '25 | Sell | $54.58 | 5,574 | $304,228.92 | 154,828 | |
| Stephenson Pamela | IRON | Chief Commercial Officer | Feb 18 '25 | Sell | $54.58 | 3,137 | $171,217.46 | 69,529 | |
| Franchi Jean M. | IRON | Chief Financial Officer | Feb 18 '25 | Sell | $54.58 | 3,136 | $171,162.88 | 69,530 | |
| Khara Rahul | IRON | Chief Legal Officer | Feb 18 '25 | Sell | $54.58 | 1,161 | $63,367.38 | 37,583 | |
| Savage William Jacob | IRON | Chief Medical Officer | Feb 18 '25 | Sell | $54.58 | 1,638 | $89,402.04 | 68,498 | |
| Yu Jonathan Yen-Wen | IRON | Chief Operating Officer | Feb 18 '25 | Sell | $54.58 | 1,610 | $87,873.80 | 40,555 |
Latest Disc Medicine Inc. News
IRON Breaking Stock News: Dive into IRON Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Disc Medicine Insider Sold Shares Worth $2,831,987, According to a Recent SEC Filing
Simply Wall St.
2 days ago
With 65% ownership, Disc Medicine, Inc. (NASDAQ:IRON) boasts of strong institutional backing
Barrons.com
4 days ago
Victoria’s Secret, Bitdeer, and More Stocks See Activist Action
Zacks
11 days ago
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
Zacks
22 days ago
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
MT Newswires
a month ago
Disc Medicine's Annual Loss Widens in 2024
MT Newswires
a month ago
TD Cowen Initiates Coverage on Disc Medicine With Buy Rating
GlobeNewswire
a month ago
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Compare IRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.